Regenxbio (NASDAQ:RGNX) reported quarterly earnings results on March 05, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-1.30, missing the consensus estimate of $-0.91 by $0.39 per share. Revenue came in at $30.3M, missing the estimate of $39.9M.
Regenxbio's stock moved following the earnings release. The stock currently trades at $8.36 with a market capitalization of $651.0M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 43% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Regenxbio should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.